Oncology

Those with pathogenic variants had a higher likelihood of communicating with clinicians and family members about test results.

Review data demonstrated a variation in opioid prescriptions for cancer-related pain between oncology providers and pain management providers.

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.

Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.

Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

Further development of vebreltinib in patients with MET fusions is being considered following results from the phase 2 SPARTA trial.

The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Genetic testing may be beneficial post-cancer diagnosis for reducing cancer risk for families with hereditary cancer syndromes and managing treatment.

Results from a retrospective cohort study display evidence of potential benefit from GLP-1RAs for the reduction of 13 obesity-associated cancers for those with type 2 diabetes.

Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.

Julie M. Vose, MD, MBA, looks back at the 2024 ASCO Annual Meeting and highlights key presentations.

Two deaths due to presumed sepsis in patients treated in the DENALI trial led to the clinical holds on the advanced solid tumor treatment.

Joleen Hubbard, MD, explains why allowing access to results can improve patient’s outlook on treatments and understanding of their disease.

The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.

Neil M. Iyengar, MD, focuses on the use of artificial intelligence in the oncology space.

Health economists discuss their interests in the outcomes observed from the Affordable Care Act and its impact on specific populations.

Cathy Bradley, PhD, and Lindsay M. Sabik, PhD, spoke about moving the needle forward in the public health space through research and persistence.